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data of 12 test substances in the UKK and UKN1 test sys-
tems to understand the basic principles of how chemicals 
interfere with the spontaneous transcriptional development 
in both test systems. The set of test compounds included 
six histone deacetylase inhibitors (HDACis), six mercury-
containing compounds (‘mercurials’) and thalidomide. All 
compounds were tested at the maximum non-cytotoxic con-
centration, while valproic acid and thalidomide were addi-
tionally tested over a wide range of concentrations. In total, 
242 genes (252 PSs) in the UKK test system and 793 genes 
(1092 PSs) in the UKN1 test system were deregulated by 
the 12 test compounds. We identified sets of ‘diagnostic 
genes’ appropriate for the identification of the influence of 
HDACis or mercurials. Test compounds that interfered with 
the expression of developmental genes usually antagonized 
their spontaneous development, meaning that up-regulated 
developmental genes were suppressed and developmental 
Abstract Stem cell-based in vitro test systems can reca-
pitulate specific phases of human development. In the UKK 
test system, human pluripotent stem cells (hPSCs) ran-
domly differentiate into cells of the three germ layers and 
their derivatives. In the UKN1 test system, hPSCs differ-
entiate into early neural precursor cells. During the normal 
differentiation period (14 days) of the UKK system, 570 
genes [849 probe sets (PSs)] were regulated >fivefold; in 
the UKN1 system (6 days), 879 genes (1238 PSs) were reg-
ulated. We refer to these genes as ‘developmental genes’. 
In the present study, we used genome-wide expression 
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genes whose expression normally decreases were induced. 
The fraction of compromised developmental genes varied 
widely between the test compounds, and it reached up to 
60 %. To quantitatively describe disturbed development 
on a genome-wide basis, we recommend a concept of two 
indices, ‘developmental potency’ (Dp) and ‘developmental 
index’ (Di), whereby Dp is the fraction of all developmental 
genes that are up- or down-regulated by a test compound, 
and Di is the ratio of overrepresentation of developmental 
genes among all genes deregulated by a test compound. 
The use of Di makes hazard identification more sensitive 
because some compounds compromise the expression of 
only a relatively small number of genes but have a high 
propensity to deregulate developmental genes specifically, 
resulting in a low Dp but a high Di. In conclusion, the con-
cept based on the indices Dp and Di offers the possibility to 
quantitatively express the propensity of test compounds to 
interfere with normal development.
Keywords Human stem cells · Transcriptome · Genomics 
biomarkers · Developmental toxicity · In vitro test systems
Introduction
Developmental toxicity testing represents a particularly 
challenging field of toxicology because the currently applied 
animal tests, such as second-generation reproduction or 
developmental neurotoxicity studies, are cost as well as 
labour intensive and require high numbers of animals (Adler 
et al. 2011; Forsby and Blaauboer 2007; Leist et al. 2008, 
2013). In addition, developmental toxicity animal studies 
are not entirely relevant to the human situation. Therefore, 
the currently available testing capacities for studying the 
high number of developmental toxicants are not sufficient 
(Hengstler et al. 2006; Reif 2014a; Zimmer et al. 2014). A 
relatively high fraction of almost 20 % of newly approved 
drugs in Europe were reported to have post-approval issues, 
and between 2009 and 2011, five drugs had to be withdrawn 
from the market (Mol et al. 2013). Moreover, the chemical 
industry has been confronted with the European regulation 
on Registration, Evaluation, Authorisation and Restriction 
of Chemicals (REACH) initiative to provide more detailed 
toxicological data (Hengstler et al. 2006). Therefore, large 
efforts have been made to develop human stem cell-based 
in vitro test systems (Hengstler et al. 2006; Meganathan 
et al. 2015; Shinde et al. 2015; Weng et al. 2014). These 
in vitro systems recapitulate the critical phases of develop-
ment, during which they are exposed to test compounds 
(Krug et al. 2013). Meanwhile, these systems have been 
applied in numerous studies to identify and characterize 
developmental toxicants (Balmer et al. 2014; Meganathan 
et al. 2012, 2015; Sisnaiske et al. 2014; Zimmer et al. 2014). 
Genome-wide expression studies have been performed to 
classify developmental toxicants (Rempel et al. 2015), and 
an eight-gene classifier has been shown to distinguish com-
pounds acting as histone deacetylase inhibitors (HDACis) 
from a heterogeneous group of ‘mercurials’. Moreover, 
concentration-dependent, genome-wide expression studies 
in such stem cell-based systems have revealed concentration 
progression principles that allow the differentiation of (1) 
tolerated concentrations, where no gene expression changes 
are induced, (2) teratogenic concentrations ranges, where 
critical developmental genes are deregulated but no cyto-
toxicity occurs and (3) cytotoxic concentrations (Waldmann 
et al. 2014).
A specific feature of stem cell-based developmental 
in vitro tests is that they represent dynamic systems. Dur-
ing the test period, when stem cells differentiate, for exam-
ple, to cells of the three germ layers, some hundreds of 
genes are up- or down-regulated (‘developmental genes’), 
while expression of the majority of the approximately 
22.000 genes of human cells remains unaltered (‘static 
genes’). Although much progress has been achieved in the 
field of developmental in vitro tests in the past decade (Reif 
2014b; Stober 2014), a comprehensive analysis differenti-
ating the influence of chemicals on ‘developmental’ versus 
‘static’ genes and their role in developmental toxicity in 
Fig. 1  Data structure of transcriptome changes triggered by histone 
deacetylase inhibitors (HDACis) and mercurials in two human stem 
cell systems differentiating towards all three germ layers (UKK) 
and neuroectoderms (UKN1). a Stem cells were either differentiated 
towards all three germ layers (UKK) for 14 days (DoD 14) or towards 
neuroectoderms (UKN1) over 6 days of differentiation (DoD 6), as 
indicated. b The highest non-cytotoxic concentration, corresponding 
to EC10, of all test compounds was determined in a viability assay. 
This ‘benchmark concentration’ (BMC) was used for obtaining tran-
scriptome data of HDACis and mercurial exposure. The BMCs were 
calculated based on the concentration–response curves of three inde-
pendent experiments. c The data structure of all transcriptome data 
sets was dimensionality-reduced and presented in the form of a 2D 
principle component analysis (PCA) diagram. The PCA illustrates 
a relatively large distance between human embryonic stem cells 
(hESCs) and differentiated cells at DoD 14 in the UKK system (UKK 
control) and at DoD 6 in the UKN1 system (UKN1 control). d Isoci-
trate dehydrogenase (ICDH) was incubated for 20 min with mercu-
rials at the indicated concentrations. Isocitrate and NADP+ were 
added to determine the ICDH activity photometrically by measuring 
the reduction of NADP+ to NADPH. The ICDH activity is repre-
sented as a percentage relative to untreated control enzyme (dashed 
line). Glutathione reductase (GSR) was incubated for 20 min with 
the respective mercurials at the indicated concentrations. GSR activ-
ity was determined photometrically and is represented as a percent-
age relative to untreated control enzyme (solid line). The BMCs of 
the respective mercurials (used in this study for microarray analysis) 
are indicated by a red line (UKK) and a blue line (UKN1); data are 
shown as the mean ± SD; n = 3. e, f PCA analysis (using the 50 
most regulated genes, defined by the lowest FDR-corrected p value) 
was performed separately for the two systems, including the 12 toxi-
cants (n = 4) plus the untreated control (n ≥ 8) investigated in them 
(colour figure online)
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humans has not yet been performed. To achieve more pro-
gress in this field, we used two recently introduced in vitro 
systems of human developmental toxicity: the UKK (Uni-
versitätsklinikum Köln) test system, which recapitulates 
the development of human embryonic stem cells (hESCs), 
or alternatively, of other pluripotent stem cells (hPSCs), 
to the three germ layers and their derivatives during a 
14-day differentiation process, and the UKN1 (University 
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of Konstanz) test system, which represents a 6-day pro-
cess of hESCs/hPSCs differentiating into neural precursors 
(Fig. 1a; Krug et al. 2013). We focused on genome-wide 
expression data of six ‘mercurials’, a relatively heteroge-
neously acting group of chemicals containing mercury in 
their molecules, and we compared their effects to those 
of six histone deacetylase inhibitors, representing a rela-
tively homogeneous group of compounds with a similar 
mechanism of action. We report that the influence on devel-
opmental as well as static genes is highly compound spe-
cific. Moreover, different developmental processes, such as 
the induction of the germ layer or different somatic cells, 
or specific neural induction, show differential susceptibil-
ity to individual test compounds. In the present study, we 
introduce two basic developmental indices to characterize 
the potency of developmental toxicants: (1) developmental 
potency (Dp), which represents the fraction of developmen-
tal genes among all genes whose expression is influenced 
by a test compound, and (2) developmental index (Di), 
which describes the degree to which developmental genes 
are overrepresented among all genes deregulated by a test 
compound. These parameters can easily and precisely be 
determined and represent a sound starting point for a more 
detailed understanding of the disturbed development of dif-
ferentiating stem cells. Overall, the tests are based on stem 
cell and omics technologies and have a high predictive 
potency for discriminating between general and develop-
mental toxicity. Accordingly, we have named the UKK test 
system as the STOP-Toxukk test and the UKN1 system as 




Gelatin, putrescine, selenium, progesterone, apotransferrin, 
glucose and insulin were obtained from Sigma (Steinheim, 
Germany). Accutase was obtained from PAA (Pasching, 
Austria). FGF-2 (basic fibroblast growth factor), noggin 
and sonic hedgehog were obtained from R&D Systems 
(Minneapolis, MN, USA). Y-27632, SB-43154 and dorso-
morphin dihydrochloride were obtained from Tocris Bio-
science (Bristol, UK). MatrigelTM was obtained from BD 
Biosciences (Massachusetts, USA). All cell culture rea-
gents were obtained from Gibco/Invitrogen (Darmstadt, 
Germany), unless otherwise specified. The following chem-
icals (HDACis and mercurials) were obtained from Sigma 
unless otherwise specified. The vehicles used are also men-
tioned with the compounds: (HDACis) valproic acid (VPA, 
P4543; water); trichostatin (TSA, T1952; DMSO); vori-
nostat (SAHA, SML 0061; DMSO); belinostat (PXD101, 
S1085, Selleckchem; DMSO); panobinostat (LBH589, 
S1030, Selleckchem; DMSO); entinostat (MS-275, Cay-
13284-25; Biomol; DMSO); (mercurials) methylmercury 
(MeHg, 442,534; 10 % ethanol); thimerosal (THM, T4687; 
water); mercury(II)chloride (HgCl2, 203,777; water); 
mercury(II)bromide (HgBr2, 437859, water); 4-chloromer-
curibenzoic acid (PCMB, C5913-5G; water); and phe-
nylmercuric acetate (PMA, P27127-25G).
Human embryonic stem cells
The human pluripotent stem cell line H9 (Thomson et al. 
1998) was obtained as a WA09 line from WiCell (Madison, 
WI, USA). The importation of the cells and the subsequent 
experiments were authorized (Robert Koch Institute, Ber-
lin, Germany) under licence # 170-79-1-4-27 for the UKN1 
system and licence # 1710-79-1-4-34 for the UKK system. 
H9 cells were cultured on irradiated mouse embryonic fibro-
blasts (MEFs) in H9 culture medium, as previously described 
(Jagtap et al. 2011; Krug et al. 2013; Shinde et al. 2015).
Random differentiation of hESCs to germ layer cell 
types and their derivatives (UKK test system)
To remove MEFs, H9 cells from the maintenance cul-
ture were transferred on hESC-qualified matrix (BD Bio-
sciences, California, USA)-coated, 60-mm tissue cul-
ture plates (Nunc, Langenselbold, Germany) in TESR1 
medium (StemCell Technologies) and were maintained for 
5 days prior to differentiation. The random differentiation 
into embryoid bodies (EBs) representing multiple line-
ages was performed as described previously (Meganathan 
et al. 2012). In brief, cell clumps were obtained by cut-
ting and scraping the cells with a passage tool (StemPro 
EZPassage™ Disposable, Invitrogen) and a cell scraper. 
On day 0, 80 clumps were seeded in each well of a plu-
ronic-coated, v-bottom plate in 100 µl of random differen-
tiation (RD) medium (DMEM-F12 medium with 20 % KO 
serum replacement, 1 % non-essential amino acids, penicil-
lin (100 units/ml), streptomycin (100 µg/ml) and 0.1 mM 
β-mercaptoethanol) containing chemical or vehicle, and the 
plate was then incubated (37 °C, 5 % CO2) for 4 days. The 
EBs were collected on day 4 and were transferred onto a 
100-mm bacteriological plate in 15 ml of RD medium con-
taining the chemical or vehicle. The medium was replen-
ished every alternate day until day 14 of differentiation.
Neuroepithelial differentiation (UKN1 test system)
H9 cells were cultured according to standard protocols 
and were differentiated into neuroepithelial progenitors 
(NEPs) as previously described (Balmer et al. 2014; Krug 
et al. 2013; Shinde et al. 2015) and as shown in Fig. 1. The 
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differentiation of the H9 cells towards NEPs was based on 
a dual SMAD inhibition (Chambers et al. 2009) using a 
combination of 35 µM noggin and 600 nM dorsomorphin 
together with 10 µM SB-431642. This was used to prevent 
BMP and TGF signalling and thus achieve a highly selec-
tive neuroectodermal lineage commitment. Cells were han-
dled and manipulated as previously described in the sup-
plemental methods (Balmer et al. 2014).
Benchmark concentration (BMC) determination
The BMC is defined here as the concentration at which at 
least 90 % of the cells survive (BMC10). For both test sys-
tems, the BMC10 was determined for six HDACis and six 
mercurial compounds by performing resazurin cell viability 
assays exactly as previously described (Krug et al. 2013; 
Stiegler et al. 2011). In the UKK system, the H9 cells were 
differentiated as described above and were treated from 
DoD 4 to DoD 14. In the UKN1 test system, the cells were 
treated from DoD 0 to DoD 6. Both test systems were 
treated during the indicated time periods with concentra-
tions ranging from non-cytotoxic to cytotoxic. The analy-
sis was performed on DoD 14 (UKK) and DoD 6 (UKN1). 
The experiments have been performed with five technical 
and three biological replicates. On the day of analysis, 
cells were incubated with 10 µg/ml resazurin for 1–1.5 h at 
37 °C and 5 % CO2. To determine the background fluores-
cence of resazurin itself, a control with only resazurin in 
medium was included. Resorufin was measured at a wave-
length of 560Ex/590Em with a fluorescence reader. The 
mean background fluorescence of resazurin was subtracted 
from all experimental data. Further data processing to iden-
tify BMC of chemicals was done as mentioned below. Data 
from each experiment were normalized to their respective 
vehicle controls (set as 100 %). The data were then dis-
played in semi-logarithmic plots. Data points were con-
nected by a nonlinear regression sigmoidal dose–response 
curve fit. These curves were averaged, and BMC10 was 
then determined graphically as the data point on the aver-
age curve corresponding to 90 % viability value, or as the 
last real data point left of this value. The BMC10 con-
centrations of the compounds were considered for further 
Affymetrix-based studies with UKK and UKN1 protocol.
Affymetrix‑based study details
For Affymetrix-based study, six HDACis and six mercu-
rial compounds were exposed at BMC10 concentrations 
from DoD 0 to DoD14 or from DoD 0 to DoD6 in UKK or 
UKN1 test system, respectively, along with the respective 
vehicle controls. The samples were collected on DoD 14 or 
DoD 6 for RNA isolation. The samples from four biologi-
cal replicates were used for further processing.
Affymetrix DNA microarray analysis
On DoD 14 (UKK) or DoD 6 (UKN1), medium was 
removed, and the cells were lysed in RNA protect solu-
tion (Qiagen). Affymetrix chip-based DNA microarray 
analysis (Human Genome U133 plus 2.0 arrays) was per-
formed exactly as previously described (Krug et al. 2013; 
Meganathan et al. 2015). Briefly, total RNA was isolated 
using TRIzol and chloroform (Sigma, Steinheim, Ger-
many) and purified with miRNeasy mini kit (Qiagen, 
Hilden, Germany). The quantification and quality control 
measurements were done using Nanodrop spectrophotom-
eter (ND-1000, Thermo Fisher, Langenselbold, Germany). 
For microarray labelling 100 ng total RNA was taken as a 
starting material, and after amplification 12.5 µg amplified 
RNA was hybridized on Affymetrix Human Genome U133 
Plus 2.0 arrays (Affymetrix, Santa Clara, CA, USA). For 
washing and staining Affymetrix HWS kit and Genechip 
Fluidics Station-450 were used according to the manufac-
turer’s instructions. After staining arrays were scanned with 
Affymetrix Gene-Chip Scanner-3000-7G and Affymetrix 
GCOS software has been used for quality control analy-
sis. The corresponding raw CEL files of the Affymetrix 
chips are publicly available under GEO accession number 
GSE71127.
Biostatistics
Batch effects, non-biological experimental variation, is a 
commonly observed phenomenon in the area of microar-
ray studies. They occur due to experiments that cannot be 
conducted all at once, for various reasons. It was important 
to eliminate batch effects as otherwise relevant expression 
changes may remain undetected. We applied the ComBat 
algorithm (Johnson et al. 2007) that allowed adjusting for 
batch effects in datasets where the batch covariate was 
known. It used a nonparametric, empirical Bayes approach 
for the estimation of an additive and a multiplicative batch 
effect. First, we used extrapolation strategy (RMA +) (Har-
bron et al. 2007) for background correction, log2 trans-
formation and quantile normalization. Then the data were 
standardized with respect to mean gene expression and 
treatment effect. Then, the batch effects were estimated 
and eliminated from the standardized data by subtracting 
the additive effect and dividing by the multiplicative effect. 
Finally, the data were back-transformed, i.e. mean gene 
expression and treatment effect were added. Further statis-
tical data analysis and visualization performed by upload-
ing ComBat-corrected files into the Partek Genomics Suite 
(PGS) version 6.6 software (Partek, St. Louis, MO, USA). 
The normalized probe sets (PSs) were used for the genera-
tion of a principal component analysis (PCA) and one-way 
ANOVA model that was used to identify the differentially 
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regulated transcripts with changes of at least 1.5-fold 
(absolute fold change, p value ≤0.05), with Benjamini and 
Hochberg FDR corrections. The first 50 transcripts deregu-
lated by each toxicant were filtered based on p value, and 
signals were normalized by z-score and clustered using a 
hierarchal cluster analysis (complete linkage method). The 
commonly deregulated transcripts were obtained using a 
Venn diagram overlap analysis (PGS). Online free software 
such as g:Profiler and the Database for Annotation, Visu-
alisation and Integrated Discovery (DAVID) were used for 
functional annotation and gene ontology (GO) clustering of 
differentially expressed transcripts (p ≤ 0.05).
Construction of a transcription factor network
The TF network was constructed as previously described 
(Rempel et al. 2015). Briefly, we downloaded raw data for 
the microarray samples referenced in the manually curated 
CellNet tissue atlas (Cahan et al. 2014) and combined them 
with data from the UKN1 and UKK test systems (Balmer 
et al. 2014; Cahan et al. 2014; Krug et al. 2013; Waldmann 
et al. 2014). To obtain the expression matrix, the samples 
were normalized together using RMA implemented in the 
R package oligo. The co-expression network was con-
structed in two steps using functions from the parmigene 
package for R. First, the mutual information matrix was 
computed by applying the function knnmi.all with param-
eter k = 9, chosen based on an unpublished benchmarking, 
on the expression matrix. Then, we applied the clr function 
from the parmigene package, which implements the CLR 
algorithm. The co-expression network was subsequently 
restricted to genes annotated as transcription factors (TFs) 
in the Animal Transcription Factor Database (AnimalT-
FDB, [http://www.bioguo.org/AnimalTFDB/index.php]). 
The overlap of the genes detected by the Affymetrix array 
and the AnimalTFDB was 1300 genes. Links were drawn 
only for pairs of TFs with a score in the top 0.1 % of all 
co-expression scores. This yielded 1690 predicted interac-
tions between 847 TFs. Nodes were arranged in the net-
work according to the Fruchterman and Reingold’s force-
directed placement algorithm provided by the R package 
sna with the area parameter = 109.
Representation of mercurials or HDACis consensus genes 
on the TF network
Communities of network nodes were determined by the 
fast greedy community function of the R package igraph. 
Only the top 18 largest communities were analysed for 
the enrichment of GO biological process annotations, as 
the others contained less than six genes. The enrichment 
analysis was performed with the R package topGO using 
the classic method and the Fisher’s test statistic. We 
selected representative terms for each community from 
the top enriched terms with an unadjusted p value <0.05. 
For spontaneous differentiation and regulation by com-
pounds, TFs in the network were marked red (blue) if a 
probe set mapping to this TF was up-regulated (down-
regulated) under the respective condition. The mapping of 
PSs to the Ensembl gene ids and gene symbols was deter-
mined using the BioConductor package hgu133plus2.db. 
Only PSs that could be mapped to a gene symbol were 
taken into account. TFs for which PSs mapping to them 
were inconsistently regulated were removed from the 
analysis.
Glutathione reductase (GSR) and isocitric dehydrogenase 
(ICDH) activity assays
ICDH (porcine, Sigma, I-2002) (10 µg/200 µl) in a 
Tris(hydroxymethyl)-aminomethane (Tris)-buffer (20 mM) 
containing MnSO4 (2 mM), pH 7.4, was incubated with the 
compounds to be tested at 37 °C for 20 min. ICDH activity 
was determined by the addition of isocitrate (4 mM) and 
NADP+ (0.1 mM). The enzymatic reduction of NADP+ 
to NADPH was monitored using photospectroscopy at 
340 nm over the course of 15 min at 1-min intervals and 
37 °C. The enzymatic activity was determined from the 
slope of the absorbance increase over time. All data were 
normalized to the activity of untreated enzyme (i.e. free of 
toxicant). GSR (human, Sigma G-9297) (10 µg/200 µl) was 
incubated in sodium phosphate buffer (100 mM), pH 7.5, 
containing ethylenediaminetetraacetic acid (EDTA; 1 mM) 
and the compounds to be tested for 20 min at 37 °C. To 
assess GSR activity, oxidized glutathione (GSSG) (5 µM), 
NADPH (0.4 mM) and 5,5′-dithiobis(2-nitrobenzoic acid) 
(DTNB) (all from Sigma) were added, and the reaction 
was monitored by absorbance measurements at 405 nm 
(37 °C) at 1-min intervals over the course of 15 min. The 
enzymatic activity was determined from the slope of the 
absorbance increase over time. All data were normalized 
to the activity of untreated enzyme (i.e. free of toxicant).
Identification of consensus genes
A gene was defined as significantly deregulated by a spe-
cific compound if at least one annotated probe set was 
significantly deregulated (absolute fold change >1.5 and 
FDR-corrected p value <0.05). A gene was defined as a 
‘consensus’ gene if it was significantly up- or down-regu-
lated by as many compounds of same class as possible (i.e. 
mercurial or HDACi).
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Identification of diagnostic genes
A ranking approach was performed to identify PSs that 
fulfilled the following criteria: (1) deregulation occurred 
from as many compounds of the same class as possible (i.e. 
HDACi or mercurial); (2) PSs with higher fold changes 
compared with those of the controls were preferentially 
considered; (3) only the developmental genes were con-
sidered; (4) PSs were only considered when the test com-
pounds antagonized the spontaneous development, i.e. 
when up-regulated developmental genes were suppressed 
or down-regulated developmental genes were induced; (5) 
only PSs with baseline expression values >6 (log2 scale) 
at day 0 or at the day of differentiation (day 14 in the UKK 
system or day 6 in the UKN1 system) were considered (the 
number of PSs passing this criteria are shown in Suppl. 
Fig. S5A &B, the cut-off value has been selected based on 
the frequency distribution curves provided in Suppl. Fig. 
S5C & D); and (6) PSs were only considered when they 
could be assigned to genes whose function is basically 
understood.
Results
Structure of developmental genes in differentiating 
stem cells
In the present study, two stem cell-based test systems were 
used, the UKK system, where hESCs/hPSCs differentiate 
into cells of the three germ layers and their derivatives, and 
the UKN1 system, which recapitulates differentiation into 
early neural precursor cells (Fig. 1a). Genome-wide gene 
expression profiles were established from the undifferenti-
ated hESCs and after 14 (UKK) and 6 days (UKN1) of dif-
ferentiation. Additionally, hESCs of both in vitro systems 
were exposed to 12 test compounds at benchmark concen-
trations of low cytotoxicity during the differentiation peri-
ods. Among them, six mercurials and six HDACis were 
applied (Fig. 1b, c). All compounds were tested at their 
maximum non-cytotoxic concentrations, i.e. at the bench-
mark concentration (BMC10) resulting in a maximal viabil-
ity reduction of 10 %. This biological-anchoring point has 
been previously found to be well suited for transcriptome 
analysis (Waldmann et al. 2014). Moreover, it is also well 
correlated with known pharmacological and toxicological 
molecular properties of the test compounds. For instance, 
the concentrations of the HDACis were all within the range 
known to be required for half-maximal enzyme inhibition 
in biochemical assays (Rempel et al. 2015). The concen-
trations of the mercurials were all in a similar range with 
respect to the inhibition of thiol-containing, redox-sensi-
tive enzymes. Glutathione reductase (GSR) or isocitrate 
dehydrogenase (ICDH) were chosen as target enzymes for 
this rough bioequivalence test, and the BMC10 test con-
centrations all led to partial enzyme inhibition (Fig. 1d). 
Notably, none of the HDACis affected the enzyme activi-
ties at the concentrations tested here. To obtain an overview 
over the genome-wide data, principle component analysis 
(PCA) plots were established. The PCA illustrates a rela-
tively large distance between hESCs and the cells resulting 
after the 14-day (UKK) and 6-day (UKN1) differentiation 
processes (Fig. 1c). Compared with these large distances, 
the influence of the test compounds appears comparatively 
small (Fig. 1c). However, when the PSs for the PCA analy-
sis were limited to the 50 most regulated (defined by the 
lowest FDR-corrected p values) of each test substance, 
most compounds cluster distinctly from the controls, 
whereby the differentiation between compound-exposed 
samples and their controls appears more separated in data 
from the UKN1 system than in data from the UKK system 
(Fig. 1e, f).
Subsequently, we addressed genes whose expression 
alters spontaneously during the differentiation of stem 
cells. Genes that are up- or down-regulated during differ-
entiation into the germ layers and their derivatives (UKK) 
or into neuronal precursor cells (UKN1) will be further 
referred to here as ‘developmental genes’. There were no 
major differences in the number of developmental up-reg-
ulated genes in the UKK and UKN1 systems, but fewer 
genes were down-regulated in the UKK system (Fig. 2a). 
The overlap of developmental genes between the UKK 
und UKN1 systems was relatively small (Suppl. Table 1). 
A relatively high fraction of developmental genes showed 
high fold changes (Suppl. Table 1). The number of PSs 
up-regulated by at least fivefold (absolute value, p < 0.05; 
FDR-adjusted) was 545 specifically in the UKK system, 
489 specifically in the UKN1 system, and 99 PSs were up-
regulated in both systems. The corresponding numbers of 
down-regulated PSs were 132, 577 and 73, respectively. 
Although there was little overlap of the strongest up- or 
down-regulated developmental genes between the UKK 
and UKN1 systems (Fig. 2b), the gene ontology (GO) 
categories of both systems was similar, with a high frac-
tion of development-associated motives (Table 1). Further 
differentiation of the development-associated GO groups 
into neuronal and non-neuronal development illustrated 
that a higher number of neuronal development-associated 
GO groups was down-regulated in the UKN1 system 
compared with that in the UKK system (Fig. 2c; Suppl. 
Table 2). A similar conclusion was obtained by the analy-
sis of PSs associated with nervous system development. 
No nervous system development-associated PSs were sig-
nificantly down-regulated in the UKK system compared 
with the 139 that were in the UKN1 system (Suppl. Fig. 
S1). To obtain a deeper understanding of the differentiation 
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Fig. 2  Characterization of the two test systems, UKK (three germ 
layer) and UKN1 (neuroectoderm), by transcriptome analysis. 
Human ESCs were differentiated as indicated in Fig. 1a and were 
used for whole-transcriptome analysis. a Number of up-(red) and 
down-(blue) regulated PSs at DoD 14 in the UKK system and at 
DoD 6 in the UKN1 system (D-genes). The overlap of D-genes in the 
UKK and UKN1 test systems up- and down-regulated by ≥fivefold is 
shown (detailed data are shown in supplemental materials). b Top 20 
significantly up-(red) and down-(blue) regulated genes for the UKK 
system (left) and the UKN1 system (right). c The gene ontology (GO) 
categories belonging to biological processes overrepresented amongst 
up- and down-regulated genes (p < 0.05) were subcategorized into 
three classes: ‘neuronal development’, ‘non-neuronal development’, 
and ‘others’. The number of these overrepresented GO categories 
up- and down-regulated in the UKK and UKN1 systems are shown. 
d CellNet analysis shows the ESC classification score for ESCs and 
differentiated cells at DoD 14 in the UKK system and at DoD 6 in 
the UKN1 system (detailed data for the tissue classification scores are 
shown in the supplemental materials) (colour figure online)
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process in the UKK and UKN1 systems, we performed a 
gene regulatory network analysis (CellNet), which quan-
tifies how closely engineered cell populations resemble 
specific human cell types (Cahan et al. 2014; Godoy et al. 
2015). CellNet showed a decrease in the ESC score after 
the differentiation period in both systems, UKK and UKN1 
(Fig. 2d). However, the increase in tissue classification 
scores was only small (Suppl. Fig. S2), which was expected 
because the cells generated in the UKK and UKN1 sys-
tems are known to represent precursor and not yet mature 
cell (Krug et al. 2013). While the UKN1 system reached 
the highest tissue classification score for neuronal cells, the 
UKK system scored higher for a broader set of cell types, 
including lung, skin, liver, kidney and heart cells as well 
Table 1  Top 10 gene ontology categories overrepresented amongst up- and down-regulated probe sets during differentiation
Regulation System Neuronal p value Non-neuronal p value
UP ↑ UKK Nervous system development 5.1E−56 Anatomical structure dev. 2.3E−45
Neurogenesis 5.5E−42 Developmental process 8.0E−44
Generation of neurons 1.7E−41 Tissue development 5.1E−23
Neuron differentiation 6.2E−37 Epithelium development 1.0E−16
Central nervous system development 6.3E−32 Muscle tissue development 1.7E−14
Brain development 3.5E−26 Striated muscle tissue dev. 2.6E−14
Neuron development 6.2E−26 Connective tissue development 7.5E−13
Regulation of nervous system dev. 1.8E−24 Mesoderm development 1.2E−03
Forebrain development 5.3E−23 Endothelium development 1.3E−03
Neuron projection development 3.0E−21 Palate development 2.9E−03
UKN1 Nervous system development 6.2E−19 Single-organism dev. process 5.1E−12
Generation of neurons 5.1E−13 Head development 2.4E−10
Central nervous system development 1.0E−12 Regulation of dev. process 9.1E−10
Neurogenesis 1.8E−12 Anatomical structure dev. 2.5E−09
Forebrain development 5.8E−11 Multicellular organismal dev. 1.4E−08
Neuron differentiation 6.4E−11 Anatomical structure morphogenesis 1.4E−08
Brain development 3.1E−10 System development 2.1E−07
Regulation of nervous system dev. 7.5E−08 Cell differentiation 9.1E−07
Negative reg. of nervous system dev. 4.1E−07 Negative regulation of cell dev. 9.8E−07
Negative reg. of neurogenesis 1.5E−06 Regulation of organismal dev. 1.4E−06
DOWN↓ UKK Anatomical structure development 2.7E−12
Single-organism dev. process 1.3E−11




Anatomical structure morphogenesis 2.6E−07
Tissue development 5.0E−07
Anatomical structure formation 4.1E−06
Circulatory system development 2.6E−05
UKN1 Neuron projection dev. 5.2E−07 Anatomical structure morphogenesis 8.4E−26
Neuron projection morphogenesis 3.5E−06 System development 1.3E−24
Neuron development 1.8E−05 Tissue development 1.7E−24
Nervous system development 2.1E−05 Anatomical structure development 1.1E−23
Neurogenesis 3.1E−05 Developmental process 5.8E−21
Generation of neurons 5.6E−05 Multicellular organismal development 1.5E−20
Neuron differentiation 1.6E−04 Single-organism dev. process 3.8E−19
Axon development 1.9E−04 Circulatory system development 7.4E−19
Cell morphogenesis in neuron diff. 3.7E−04 Cardiovascular system development 7.4E−19
Axonogenesis 4.9E−04 Organ development 2.7E−18
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as fibroblasts (Suppl. Fig. S2). The results of the regulatory 
network analysis are in agreement with the concept that the 
UKK differentiation protocol allows the development of all 
three germ layers and their derivatives, while development 
within the UKN1 system is guided towards neuronal pre-
cursors, and the development of further cell types is sup-
pressed. Although the differentiation protocols of the UKK 
and UKN1 systems did not result in qualitative (i.e. all or 
nothing) differences between the test systems, the obtained 
quantitative differences are robust, considering the rela-
tively small error margins and non-overlapping scores of 
the independent experiments (Suppl. Fig. S2).
An overview over the most differential genes, GO cat-
egories and the most deregulated genes between both 
systems is given in Fig. 3. Over 3800 PSs were differen-
tially expressed (absolute twofold difference) in the end 
stage of the UKN1 and UKK cell systems. When the anal-
ysis was limited to differentially expressed genes (DEGs) 
that were at least fivefold difference (or tenfold, absolute 
values, for the UKK system), 112 (45) PSs were found to 
be more highly expressed in the UKN1 system, and 440 
(181) were more highly expressed in the UKK system 
(Fig. 3a). An analysis of overrepresented GOs amongst 
the DEGs (5-fold difference) showed a highly significant 
enrichment of GO terms (p < 10E−10), such as ‘neuron 
migration’, ‘collagen fibril organization’ and ‘anterior/
posterior pattern specification’. However, many of the 
terms were overrepresented both amongst DEGs that were 
Fold change 2x 5x 10x
UP ↑ in UKN1 vs UKK 1325 112 45
UP ↑ in UKK vs UKN1 2529 440 181
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Fig. 3  Direct comparison of the end-stage cells in the UKK and 
UKN1 test systems by transcriptome analysis. Human ESCs were dif-
ferentiated as indicated in Fig. 1a and were used for whole-transcrip-
tome analysis. a The number of differentially expressed PSs (fold 
change ≥2-/5-/10-fold, FDR-corrected p value <0.05) in the UKN1 
system compared with the UKK system. b The top 10 overrepre-
sented GO terms amongst ≥fivefold differentially expressed genes 
are shown. The top 10 GO terms were sorted by similarity, and the 
colours highlight identical GO terms. c The top 40 significantly up-
regulated (blue) PSs in the UKN1 system compared with the UKK 
system and up-regulated (red) PSs in the UKK system compared with 
the UKN1 system, sorted by fold expression. The PSs were marked 
according their role in superordinate cell biological processes: ‘early 
neural development’ (blue encircled), ‘neuronal development/func-
tion (yellow), ‘extracellular matrix proteins/cytoskeleton/cell growth 
(cyan) and non-neural development (pink) (colour figure online)
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Dark green:
FC ≥ ±1.5; *FDR corrected p value ≤ 0.05 
FC ≥ ± 1.5; *FDR corrected p value ≤ 0.05
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Fig. 4  Characterization of transcriptional changes induced by HDA-
Cis and mercurials, and identification of toxicant class consensus 
genes for the UKK and UKN1 systems. Differentiating cells were 
treated with mercurials and HDACis as indicated in Fig. 1a and were 
used for transcriptome analysis. a The 50 most significant transcripts 
de-regulated by each toxicant were used for hierarchical cluster anal-
ysis (complete linkage method). The results are represented as a heat 
map, with each column representing one experiment, each row indi-
cating data for one probe set, and the colour of each cell indicating 
the row-wise z-score of gene expression levels (blue indicates low 
and red indicates high). b The number of differentially expressed PSs 
(fold change ≥±1.5, FDR-corrected p value < 0.05) after exposure 
to toxicants compared with those of untreated controls (detailed data 
are shown in supplemental materials). c Amongst the differentially 
expressed PSs, the number of PSs that were up- and down-regulated 
by exactly 1, 2, 3, 4, 5 or 6 mercurials or HDACis in the UKK and 
UKN1 systems were counted. The columns in the cross table indicate 
how many PSs were up-(or down-) regulated, e.g. by four mercurials. 
For instance, 64 PSs were up-regulated in the UKN1 system by four 
mercurials, and 10 PSs were down-regulated in the UKK system by 
four HDACis. The number of PSs that were influenced by at least one 
toxicant was referred to as T-genes and is outlined in red (detailed 
data for the consensus genes are shown in supplemental materials). 
Mercurial consensus genes were identified in the UKK system (dark 
green, regulated by at least 3 compounds) and the UKN1 system 
(light green, regulated by at least 4 compounds). HDACis consen-
sus genes were identified in the UKK system (brown, regulated by at 
least 4 compounds) and the UKN1 system (light orange, regulated by 
at least 5 compounds) (colour figure online)
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high in the UKK system and those that were high in the 
UKN1 system (Fig. 3b). A potential explanation for this 
unexpected, but interesting, result is that genes from these 
domains are dynamically regulated in both systems and are 
thus most likely to show differential expression from sys-
tem to system. It has been previously demonstrated that the 
analysis of overrepresented GO terms is often not a very 
sensitive method to unravel complex biological regulations 
(Kuegler et al. 2010; Zimmer et al. 2011). For this reason, 
the most strongly differentially expressed genes were iden-
tified and scrutinized individually (Fig. 3c). Amongst the 
top 40 UKN1-specific genes, a larger group was found to 
be involved in early neural development and cell growth, 
consistent with the very early developmental status of cells 
in this test system. Amongst the UKK-specific genes, three 
conspicuous groups were identified: ‘neuronal develop-
ment/function’, ‘extracellular matrix proteins/cytoskel-
eton’, and ‘non-neural development’. This observation is 
well in line with the UKK system allowing for the matu-
ration of neural cells towards neurons, with the parallel 
development of non-neuronal cells, and with the more tis-
sue-like structure of the 3-dimensional aggregates of that 
test system (Fig. 3c).
Interference of chemicals with stem cell differentiation
Compared with the large gene expression alterations dur-
ing the differentiation periods of the UKK and UKN1 test 
systems, the impact of chemicals appears comparatively 
small in the PCA overview (Fig. 1c). Nevertheless, sev-
eral chemicals, particularly the HDACis, caused a shift 
of the exposed samples away from the respective controls 
(Fig. 1e, f). Cluster analysis based on the 50 most regu-
lated PSs (defined by the lowest FDR-corrected p value) 
by each toxicant (all in cases regulated PS <50) illustrates 
the separation of solvent controls from the compound-
exposed samples (Fig. 4a). The numbers of significantly 
deregulated PSs (FDR-adjusted) were relatively high for 
most compounds, usually ranging between 100 and 3000 
up- or down-regulated genes (Fig. 4b; Suppl. Table 3). The 
mercurials HgBr2, PCMB and PMA were exceptions, as 
these caused only small expression alterations in the UKK 
system. The analysis of the size of significant expression 
alterations illustrated that much larger fold changes occur 
during the differentiation process compared with the fold 
changes induced by chemicals (Suppl. Fig. S3). Analysing 
the overlap of PSs deregulated by the compounds revealed 
a consensus signature of 90 up- and 18 down-regulated PSs 
deregulated by all 6 HDACis in the UKN1 system (Fig. 4c, 
Suppl. Table 4). For HDACis in the UKK system and for 
mercurials in both test systems, no consensus PSs for all 
six test substances could be identified (Fig. 4c). The num-
bers of the most consensual PSs are indicated by green 
(mercurials) and orange (HDACis) backgrounds in Fig. 4c, 
and the corresponding genes are summarized in Fig. 5. 
The consensus PSs for HDACis in the UKN1 test system 
have been characterized previously (Rempel et al. 2015), 
and the mercurial consensus PSs (deregulated by at least of 
3 mercurials) in the UKN1 test system are shown in Fig. 5a. 
For the UKK test system, no mercury consensus PSs were 
identified, but there was a clear group of HDACi consen-
sus genes (deregulated by at least of 4 HDACi), and this is 
shown in Fig. 5b. To study whether consensus genes were 
derived from specific biological processes triggered by toxi-
cants, overrepresented GO terms were identified amongst the 
UKN1 mercurial consensus PSs. This analysis indicated the 
up-regulation of two antioxidant stress response pathways 
(glutamate–cysteine ligase activity, required for glutathione 
synthesis; ascorbate metabolism), and two toxicant response 
pathways. Moreover, there was an indication of the regula-
tion of the anti-apoptotic response in neurons (Fig. 5c).
To further understand the coordinated regulations lead-
ing to changes of the consensus genes on a biological 
system level, disturbances of the transcription factor (TF) 
network were visualized. For this purpose, we used a 
Fig. 5  Characterization of HDACi and mercurial consensus genes in 
the UKK and UKN1 test systems. Human ESCs were differentiated 
and treated as shown in Fig. 1a and toxicant consensus genes were 
identified from the transcriptome data as shown in Fig. 4. For each 
consensus gene, the mean fold change (FC) of all six HDACis or 
mercurials in each system was calculated and used for further analy-
sis. a The top 20 up- and down-regulated mercurial consensus PSs in 
the UKN1 system (regulated by at least 4 mercurials) are displayed. 
b The top 20 up- and down-regulated HDACi consensus genes in the 
UKK system (regulated by at least 4 HDACi) are shown. c The gene 
ontology (GO) categories amongst up- and down-regulated mercu-
rial consensus genes in the UKN1 system were identified and sorted 
by p value; the top 5 (lowest p values) are displayed. d The CellNet 
database (3297 transcriptome sets from all major tissues) was used 
to construct a generic human TF network based on statistical co-
expression information and graph-theoretical design principles. Each 
node represents a TF gene, and each edge suggests co-regulation. The 
edge length is driven by the number of edges on neighbouring nodes. 
The nodes were placed according to the Fruchterman–Reingold algo-
rithm, and an optimization algorithm that maximized the modular-
ity of the division of the graph into clusters was used to define the 
clusters. Next, GO term overrepresentation analysis was performed 
for each cluster to identify its biological role (Rempel et al. 2015). 
The ‘forebrain development’ and ‘neuronal development’ as well as 
the ‘cell division’ clusters have been encircled for better visualization. 
The TFs that were found both amongst the UKK and UKN D-genes 
(regulated by ≥±5-fold, p < 0.05) were selected and highlighted in 
the TF network (red indicates up-regulation, blue indicates down-
regulation). e All TFs were identified amongst the HDACi consen-
sus genes in the UKN1 system (regulated by at least 3 HDACis) and 
were highlighted in the TF network. f All TFs amongst the mercurial 
consensus genes in the UKN1 system were identified (regulated by 
at least 3 mercurials) and were highlighted in the TF network. The 
mercurial consensus TFs that were also affected by HDACis were 
encircled green and listed below (red indicates up-regulated, blue 
indicates down-regulated) (colour figure online)
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previously generated generic TF coexpression network for 
human cells (Rempel et al. 2015). Within the network, we 
previously identified groups of three highly connected TFs 
(communities) that are enriched for GO terms relevant for 
neural development (Rempel et al. 2015). On this network, 
we then mapped and compared the TFs changing in the 
respective test systems (‘developmental TFs’). Some of 
them were specific for either the UKK or UKN1 system 
(Suppl Fig. S7). However, there were also TFs regulated in 
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are concentrated in three communities related to neuronal 
development (56 %). These three communities consist of 
two communities enriched for neuronal development GO 
terms and a third community that links the two that con-
tains stem cell factors and cell cycle regulators (Fig. 5d). 
Subsequently, we identified TFs amongst the toxicant con-
sensus genes and their positioning in the network was visu-
alized (Suppl Fig. S7). For the UKN1 test system, differ-
ent consensus TFs were visualized. For HDACis, we find 
that about one-third (32.7 %) of TFs affected by at least 
three out of six compounds in the UKN1 system mapped 
to the three communities related to neuronal development 
(Fig. 5e). For the mercurial consensus (at least 3 out of 5 
compounds), we find overall less affected TFs, and also 
a lower fraction of neuronal development TFs affected 
(26.5 %) (Fig. 5f). Taken together, the HDACi consensus 
affected TFs are more strongly concentrated in neuronal 
development than the mercurial consensus affected TFs. 
In addition, mercurial consensus TFs mapped relatively 
broadly across the TF network (Fig. 5f). Most of the TFs 
affected by mercurials were also affected by HDACis, inde-
pendent of the location in the network. Such TFs are prom-
ising candidates for master regulators that are generally 
affected by various toxicants in the test systems (Fig. 5f). 
They may be used in the future as biomarkers, and they 
may also lead to further mechanistic studies with increased 
sensitivity for examining mechanisms of toxicity.
To analyse the relationship of chemically influenced PSs 
(further referred as genes) and developmental PSs (further 
referred as genes), we next focused on the pool of genes 
deregulated by at least one of the tested chemicals, as indi-
cated by the red frame in Fig. 4c (Suppl. Table 5). Overlap 
analysis between developmental and chemically deregu-
lated genes revealed a strongly compound-dependent and 
test system-dependent pattern (Fig. 6a, b). In the UKK 
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Fig. 6  Effect of mercurials and HDACis on developmental genes 
(D-genes) in the UKK and UKN1 systems. Differentiating cells were 
treated by mercurials and HDACis as indicated in Fig. 1a and were 
used for transcriptome analysis. Genes affected by the differentia-
tion process (D-genes) were identified, as shown in Fig. 2, as well as 
toxicant-affected genes (T-genes), as shown in Fig. 4. a The overlap 
of up-regulated mercurial T-genes with up-(red) and down-(blue) 
regulated D-genes as well as the overlap of down-regulated mercu-
rial T-genes with up- and down-regulated D-genes was calculated 
for each system. The data are expressed as the fraction of D-genes 
affected by toxicants. b The same procedure was performed for the 
HDACis. Blue bars represent D-genes down-regulated and red bars 
indicate D-genes up-regulated during normal differentiation. The 
numbers on top of the bars indicate the absolute number of PSs 
affected (colour figure online)
Fig. 7  Design of transcriptome-based developmental potency (Dp) 
and developmental index (Di) to characterize toxicant-disturbed stem 
cell development. The scheme on top exemplifies the number of 
developmental PSs (D; yellow circle) that are significantly deregu-
lated during stem cell differentiation and the number of toxicity PSs 
(T; blue circle) that are significantly deregulated by a compound. In 
total, 54,675 probes are measured on the microarray chip (grey box). 
D-genes (or respective PSs) that are significantly deregulated by a 
toxicant are classified as overlap PSs/genes (O; green). The param-
eters from the scheme are used to calculate developmental potency 
(Dp) and developmental index (Di); the corresponding formula and 
key questions are given. Fisher’s exact test was used to determine 
whether there was a significant overlap of D- and T-genes. The ques-
tions were applied to various toxicity testing experiments. a–d The 
list of PSs influenced by various concentrations of valproic acid 
(VPA) in the UKN1 test system and thalidomide in the UKK test sys-
tem was retrieved from the literature (Meganathan et al. 2012; Wald-
mann et al. 2014), and Dp and Di were calculated and plotted. e, f Dp 
and Di were calculated for methylmercury (MeHg) and VPA in the 
UKK and UKN1 test systems. As a reference basis for the D-genes, 
the common D-genes of the UKK and UKN1 systems (as defined in 
Fig. 2a) were used instead of the D-genes specific for each system. 
g, h Dp and Di were calculated for six mercurials and six HDACis 
in the UKN1 and (i, j) the UKK test systems using system-specific 
D- and T-genes. The total number of D-genes (green) and T-genes 
(purple) are given on top of the bars. l, m Dp and Di were calculated 
for specific differentiation processes for VPA in the UKN1 test sys-
tem, as indicated. Detailed lists of all compound-deregulated PSs, 
developmental PSs and PSs belonging to the specific differentiation 
processes in the UKK and UKN1 test systems are provided in supple-
mental materials. *p < 0.05; **p < 0.01; ***p < 0.001 for D/T over-
lap according to Fisher’s exact test, with T-genes as indicated in the 
bar graph and D-genes for the respective test systems (colour figure 
online)
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Key question Answer Formula 
How many D genes are affected 
by a toxicant? 
Developmental 
potency 
How strongly are D genes (over)-
represented amongst T genes?
Developmental 
index 
Is there a significant overlap of D 
and T genes? Fisher's exact test
*<0.05
**<0.01 
***<0.001 O: Overlap genes














































































































































































































T-genes: see bars T-genes: see bars T-genes: see bars




















































































































854 Arch Toxicol (2017) 91:839–864
1 3
system, genes deregulated by mercurials (by at least one 
of the six tested compounds) showed only very little over-
lap with developmental genes (Fig. 6a). In contrast, a very 
high degree of overlap of more than 60 % was observed in 
the UKN1 test system. This shows that the developmental 
genes in the UKN1 system are more susceptible to mercuri-
als (Fig. 6a) and HDACis (Fig. 6b) compared with those 
of the UKK system. In contrast with mercurials, HDACis 
deregulated developmental genes in both the UKK and 
UKN1 systems, although the degree of overlap between 
compound-associated and developmental genes was also 
higher in the UKN1 system (Fig. 6b). Furthermore, a char-
acteristic feature is that most of the chemically influenced 
genes in the overlap antagonize the spontaneous develop-
ments in differentiating hESCs; genes that are induced dur-
ing development are suppressed by exposure to chemicals, 
while decreased gene expression is induced. The opposite 
constellation, the chemical induction of increased devel-
opmental gene expression or the further suppression of 
already spontaneously decreasing gene expression, was 
comparatively rare (Fig. 6). The analysis shown in Fig. 6 
is based on developmental genes that are at least fivefold 
up- or down-regulated. In a similar analysis, we differenti-
ated developmental genes deregulated by two-, five-, and 
tenfold (absolute values, Suppl. Fig. S4). This analysis 
confirmed the concept that developmental toxicants usu-
ally antagonize the spontaneous up- or down-regulation of 
developmental genes, similar to that shown in Fig. 6.
In conclusion, mercurials or HDACis usually antagonize 
the spontaneous development of gene expression in differen-
tiating hESCs. This characteristic feature was also shown by 
an alternative approach, in which high and low gene expres-
sion was differentiated using a log2 value of 6 as a threshold 
(Suppl. Fig. S5; Suppl. Table 6). An overlap of chemically up-
regulated genes mostly occurs for genes that are high in the 
undifferentiated hESCs and decrease during the differentiation 
period (Suppl. Fig. S5A, B), while chemically induced down-
regulated genes overlap with developmental genes that are 
lowly expressed in stem cells and have increased expression 
towards the end of the in vitro differentiation period. Recipro-
cal scenarios were only rarely observed (Suppl. Fig. S5).
Developmental potency (Dp) and developmental index 
(Di) for the characterization of compromised stem cell 
development
The analyses of the previous paragraph showed that 
chemicals deregulate developmental genes in a complex 
manner. Investigations such as those shown in Figs. 1, 
2, 3, 4, 5, 6 may be too complex for routine toxicologi-
cal studies. To reduce complexity, we propose two indi-
ces that are relatively easy to obtain and yet correctly 
describe how chemicals interfere with the transcriptome 
of differentiating stem cells. The most important index is 
‘developmental potency’ (Dp), which represents the frac-
tion of all developmental genes that are altered by a test 
compound at a given concentration. For the example of 
VPA in the UKN1 system (Fig. 7a; Suppl. Table 7), Dp 
increases in a concentration-dependent manner until the 
expression of more than 50 % of all developmental genes 
is compromised at the highest tested concentrations of 800 
and 1000 µM. Although the altered expression of develop-
mental genes as indicated by increased Dp is already suffi-
cient to objectify a hazard, we nevertheless recommend to 
additionally consider a second index, the ‘developmental 
index’ (Di). Di, calculated as shown in Fig. 7, yields infor-
mation about the ratio by which developmental genes are 
overrepresented among the genes deregulated by a chemi-
cal. If Di is 1.0, the fraction of developmental genes of 
all genes deregulated by the test compound corresponds 
to what can be randomly expected. If Di increases to val-
ues higher than 1.0, the chemical preferentially influences 
developmental genes. The formula for calculating Di nor-
malizes it to the total number of developmental genes 
(Fig. 7). Therefore, data from distinct cell systems such 
as UKK and UKN1 with different numbers of develop-
mental genes can be directly compared. The example of 
VPA in the UKN1 system shows that already, the low-
est concentration of 350 µM, which leads to significantly 
deregulated genes, shows a Di increased by approxi-
mately 15-fold (Fig. 7b). Interestingly, Di decreased with 
increasing concentrations of VPA; this decrease occurred 
because concentrations of 550 µM VPA and higher caused 
the expression of cell death-associated genes (Waldmann 
et al. 2014) that do not overlap with developmental genes. 
Testing very high, nearly cytotoxic concentrations can 
therefore lead to decreased Di; however, it should be con-
sidered that even at the highest tested cytotoxic concen-
tration of 1000 µM VPA, Di was still increased by more 
than fourfold. An interesting scenario of Dp and Di was 
obtained when the teratogenic thalidomide was tested in 
the UKK system (Fig. 7c, d; Suppl. Table 8). The low-
est tested thalidomide concentrations of 0.01 and 0.1 µM 
showed only a slightly increased Dp because only a few 
genes were deregulated at these concentrations. However, 
Di was already high because a high fraction of the small 
number of deregulated PSs was developmental genes. 
Therefore, 0.01 and 0.1 µM thalidomide should be already 
considered as potentially hazardous developmentally and 
teratogenic. Similarly, the benchmark concentrations for 
MeHg and VPA would be interpreted as hazardous follow-
ing the aforementioned rules of interpretation (Fig. 7e, f). 
The concept of the two developmental indices also allows 
a clear interpretation of the 12 mercurials and HDACis 
(Fig. 7g–j). It is also clear that the UKN1 system shows 
a higher susceptibility than does the UKK system for 
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both Dp and Di. As shown in Fig. 7g–j, some compounds 
resulted in negative test data because no genes were sig-
nificantly deregulated at the tested concentrations. If a test 
compound does not induce any gene expression altera-
tions over a 6- or 14-day incubation period, considering 
these test conditions as non-hazardous may be justified.
The concept of these developmental indices can be fur-
ther refined by differentiating biological categories of devel-
opmental genes. The example of VPA in the UKN1 system 
illustrates that for both Dp and Di, neural crest cell differ-
entiation was compromised to a higher degree than were 
other categories, such as neurogenesis in general, sensory 
organ development, axonogenesis and telencephalon devel-
opment (Fig. 7k, l; Suppl. Table 7 and 9). With increasing 
concentrations, the predominance of neural crest differentia-
tion decreased, probably because genes of other biological 
categories also became increasingly deregulated. In con-
trast with the UKN1 system, the UKK test system shows 
increased Dp and Di for a much broader range of catego-
ries, including limb, heart, skin and liver development after 
incubation with thalidomide (thalidomide and all further 
exposure conditions: Suppl. Fig. S6; Suppl. Table 8 and 10).
Identification of diagnostic genes
For the identification of developmental toxicants, the avail-
ability of diagnostic genes is of high relevance. The top 
diagnostic genes shown in Fig. 8 were selected from the 
consensual PSs (Fig. 4c; green and orange fields) based 
on the additional criteria as mentioned in the materials 
and method section. The baseline expression cutoff value 
has been set to be >6 (log2 scale) on day 0 or day of dif-
ferentiation based on the frequency distribution curves 
obtained with base line expression values (log2 scale) for 
all PSs on microarray (54675) of non-treated control sam-
ples on day 0 and day 6 or day 14 (Suppl. Fig. S5C & D). 
The overlap analysis of mercurial and HDACis deregulated 
PSs in UKN1 test system with the baseline expressed val-
ues (log2 scale) revealed that major overlap obtained with 
compound-deregulated PSs is with the PSs whose baseline 
Fig. 8  Identification of mer-
curial- and HDACi-induced 
diagnostic genes in the UKK 
and UKN1 test systems. For 
the identification of the top 
diagnostic genes, the follow-
ing selection criteria were used, 
as detailed in the ‘Materials 
and methods’ section: (1) regu-
lation by several compounds 
within a toxicant class; (2) base-
line expression values clearly 
higher than the Affymetrix noise 
range; (3) genes showing dis-
ease association by the online 
tool ‘DAVID’; and (4) literature 
evidence for disease association 
in animal models and humans. 
a Four diagnostic genes were 
affected by mercurials in the 
UKK test system. Five diagnos-
tic genes were up-(b) and down-
(c) regulated by HDACis in the 
UKK test system. Five diagnos-
tic genes were up-(d) and down-
(e) regulated by mercurials in 
the UKN1 test system. Five 
diagnostic genes were up-(f) and 
down-(g) regulated by HDACis 
in the UKN1 test system. The 
colours indicate the toxicant 
used; black bars give expression 
levels in undifferentiated H9 
cells; green bars give expression 
levels in untreated, differenti-
ated control cells. The data are 
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expressed values were >6 (log 2 scale) (Suppl. Fig. S5A & 
B).
Identification of gene–disease association
For identification of gene–disease association, the consen-
sus genes (Suppl. Table 4) were uploaded into the online 
tool ‘DAVID’, and genes showing disease associations 
were filtered out. The literature was searched for whether 
loss-of-function or gain-of-function mutations are known 
for these genes and whether an association with disease had 
been documented in in vivo models as well as in humans. 
The results are presented in Tables 2 and 3. Further infor-
mation was also obtained for the genes reported to be de-
regulated by the mercurials or HDACis in in vitro studies 
and their presence in consensus genes (mercurials, Table 2; 
HDACis, Table 3).
Discussion
Recently, hESC-based in vitro systems that recapitulate 
specific phases of human development have become avail-
able (Balmer et al. 2014; Krug et al. 2013; Zimmer et al. 
2014). In UKN1 and UKK test systems genome-wide 
expression data of 12 compounds (six HDACi and six 
mercurial) was obtained for benchmark concentrations 
(BMC10) resulting in viability reduced by a maximum 
of 10 %. The test compound VPA was additionally tested 
over a wide range of concentrations, from non-toxic up to 
severely cytotoxic concentrations. Additionally, the tera-
togen thalidomide was studied over a wide concentration 
range using the UKK test system. Based on this genome-
wide data set, we studied the basic principles of how 
chemicals interfere with gene expression in differentiat-
ing stem cells. One key feature is that chemicals antago-
nize the spontaneous developments of gene expression in 
differentiating stem cells. Genes up-regulated during dif-
ferentiation were suppressed, while down-regulated genes 
were induced when exposed to the test compounds. A sec-
ond key feature is that compounds differ widely in the frac-
tion of developmental genes whose expression they com-
promise. For example, VPA influences a higher fraction of 
developmental genes in both test systems than does HgCl2, 
although both compounds were tested at benchmark con-
centrations (BMC10). A third feature is the difference in 
susceptibility between both test systems. For example, a 
higher fraction of developmental genes is compromised by 
MeHg and VPA in the UKN1 system than in the UKK test 
system. Because the UKN1 system recapitulates the forma-
tion of neuronal precursor cells and the UKK system reca-
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derivatives, it can be expected that the latter process is less 
susceptible to the analysed compounds.
Considering the above-mentioned features, we recom-
mend two indices to quantify the developmental toxic-
ity potential of different compounds, the developmental 
potency index (Dp) and the developmental index (Di). Dp 
gives the intersection of the genes between the deregulated 
genes (up- or down-regulated) by a test compound and the 
genes deregulated at day 6 (UKN1) or day 14 (UKK) of 
differentiated versus undifferentiated hESCs in the absence 
of a test compound. A high Dp can be interpreted as a high 
hazard of toxicity. It should be considered that the total 
number of deregulated genes is associated with Dp. If a 
compound deregulates only a small number of genes, e.g. 
n = 20, Dp will inevitably be small. However, Dp per se 
might not discriminate developmental toxicity effects 
occurring on the expression of genes required for the dif-
ferentiation of hESCs to neural progenitor cells (UKN1) or 
for the formation of germ layer cells and their derivatives 
(UKK) from general toxicity effects not related to differen-
tiation processes (e.g. toxicity effects occur also in differen-
tiated cells). To discriminate developmental toxicity effects, 
we recommend additionally considering the developmental 
index Di. This index provides information about the ratio 
by which developmental genes are overrepresented among 
‘toxicity genes’, which represents the number of genes 
deregulated by the test compound. If Di is high, develop-
mental genes are overrepresented among ‘toxicity genes’. 
A low Di shows that developmental genes are underrep-
resented because the compound preferentially influences 
biological processes not related to development. The for-
mula of Di has been designed to consider the number of 
developmental genes. Therefore, test systems with different 
numbers of developmental genes can be directly compared. 
The relevance of Di can be illustrated by the example of the 
teratogenic compound thalidomide (Fig. 7c, d). The very 
low concentration of 0.1 µM thalidomide up-regulates only 
12 genes, resulting in a very low Dp, which does not indi-
cate a severe hazard effect. However, Di for this test condi-
tion is approximately 16, meaning that thalidomide specifi-
cally compromises the expression of developmental genes 
with a ratio 16-fold higher than can be randomly expected. 
Therefore, 0.1 µM thalidomide may be considered as devel-
opmentally hazardous, even though the expression of only 
a few genes is compromised. An opposing trend to thalido-
mide can be illustrated by thimerosal. In the UKK system, 
thimerosal deregulated 1540 PSs, which similar to 0.1 µM 
thalidomide, resulted in a low Dp. However, a Di of 1.16 for 
thimerosal indicates that developmental genes are not over-
represented among the PSs deregulated by this compound 
(Fig. 7i, j). In conclusion, using these systems with Dp and 
Di gives a rapid overview of developmental toxicity. If 
one of the two indices is high, the test condition should be 
interpreted as hazardous. Moreover, hazardous compounds 
can be classified as developmentally and less developmen-
tally hazardous compounds. In conclusion, based on this 
approach with hESCs and transcriptomic technologies, we 
have established two very sensitive test systems allowing 
the discrimination of developmental (teratogenic) toxic-
ity from non-developmental, general toxicity hazards: the 
‘STOP-Toxukn’ and the ‘STOP-Toxukk’ tests (Stem cell-
based Teratogenic Omics Prediction; UKN: University of 
Konstanz; UKK: Universitätsklinikum Köln).
Comparing the results of the two compound classes, it 
should be considered that the selected HDACis and mer-
curials showed different degrees of homogeneity. HDACis 
that have been discussed previously (Rempel et al. 2015; 
Yang et al. 2013) represent a relatively homogenous com-
pound group. This is illustrated by a consensus of 90 up- 
and 18 down-regulated genes that are influenced by all 
six HDACis in the UKN1 system. In contrast, mercurials 
showed a lower degree of overlap of deregulated genes. 
No single gene that was influenced by all six mercurials 
could be identified. Nevertheless, there is a set of consen-
sus genes influenced by five of six mercurials, which are 
appropriate to use for the identification of developmental 
toxicity in the two test systems.
A further goal of this study was to identify individual 
genes that are particularly suitable to use for the prediction 
of developmental toxicity using the test systems STOP-
Toxukk and STOP-Toxukn, further referred to as ‘diagnostic 
genes’ for severe developmental defects in humans. Prena-
tal exposure to teratogens results in congenital disorders in 
humans, which are known to be related with mutations in 
various genes (Webber et al. 2015). The disease associa-
tion of the consensus genes de-regulated by mercurials or 
HDACis further helps to understand mechanistic aspects. 
The selection criteria were that diagnostic genes should be 
influenced by as many compounds of the same class (i.e. 
HDACis and mercurials) as possible; they should show 
the highest fold changes compared with the controls; they 
should antagonize the expression of developmental genes; 
and their biological relevance should be clear, based on 
animal knockout or overexpression models or on human 
disease data. Based on these criteria, several top diagnostic 
genes were identified.
The significance of this association can be related to the 
fact that mercurials can perturb neurodegenerative genes 
by epigenetic events, resulting in altered gene expres-
sion and late onset of neurodegenerative diseases. Mer-
curial consensus genes that are related to genetic disease 
associations are the following: MTPAP, SEPW1 (UKK); 
NQO1 (UKK/UKN1); SPP1, CYP1B1, GABRB3, UCHL1, 
SLC7A5, COL1A2 and FTL (UKN1). The only up-reg-
ulated gene found in the UKK test system was MTPAP. 
Interestingly, a mutated MTPAP has been reported in 
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human autosomal-recessive spastic ataxia (Crosby et al. 
2010). Moreover, the polymorphisms or overexpression of 
the detoxification enzyme NQO1 has been reported in Alz-
heimer’s patients (Raina et al. 1999) and was captured by 
mercurials in both systems. The up-regulation of SPP1 has 
been observed in autistic children (Al-ayadhi and Mostafa 
2011). Mutations of GABRB3 have been identified and a 
role of the SLC7A5 gene has also been described in autis-
tic patients (Anderson et al. 2009; Warrier et al. 2013). 
Mutations in UCHL1 have been identified in Parkinson’s 
patients (Liu et al. 2015), whereas a gain-of-function muta-
tion in the corresponding mouse gene resulted in Parkin-
son’s disease symptoms (Yasuda et al. 2009). A mutation in 
FTL resulted in neurodegenerative hereditary ferrinopathy, 
characterized by tremor and cognitive defects (Kubota et al. 
2009; Vidal et al. 2004). The NPY2R gene has been shown 
to serve in a neuroprotective role in animal models of Par-
kinson’s disease (Decressac et al. 2012). Notably, NPY2R 
was found to be down-regulated by mercurials.
Autopsies of children exposed to MeHg in utero showed 
degeneration and atrophy of cortical structures, ectopic cell 
masses in the cortex, astrocytes present in white matter and 
cell loss prominent in the cerebellum and cerebrum (Bur-
bacher et al. 1990). The biological functions of two mer-
curial consensus genes SOX6 and THBS1 are in agreement 
with these pathologies. SOX6 was found to be down-reg-
ulated in our study, and a SOX6 mouse knockout showed 
that expression is required for normal positioning and mat-
uration of cortical interneuron subtypes (Batista-Brito et al. 
2009). THBS1 was up-regulated by the mercurials and has 
been shown to promote neurite outgrowth as well as post-
natal migration of neuronal precursor cells in mice (Liu 
et al. 2015). Additional diagnostic mercurial consensus 
genes are SEPW1 and GCLM. SEPW1 has been reported to 
be a neuroprotectant, and it is targeted by MeHg in human 
neuronal cells (Kim et al. 2005). It has also been reported 
that MeHg up-regulates GCLM in human neuroblastoma 
cells (Toyama et al. 2007). Recently, a good correlation 
between polymorphisms of SEPW1 and GCLM and the 
potential of eliminating mercurials in urine and hair has 
been reported in humans (Goodrich et al. 2011, 2013).
In animal models, inhibition of HDAC resulted in 
altered gene expression during embryonic develop-
ment that was accompanied by congenital malformations 
(Menegola et al. 2005). The data from the literature sug-
gest that VPA-induced malformations in humans are con-
genital microcephaly, atrial and ventricular septal defects, 
craniofacial abnormalities, neural tube defect spina bifida, 
urogenital abnormalities and ear abnormalities (Ardinger 
et al. 1988). HDACis regulated consensus genes that are 
linked to these malformations include ASNS, COL11A1, 
GABRB2, and GBE1 in the UKK system and RTN1, 
SMOC1, RAX, ARNT2, CASP8, MIAT, BMP5 and EDNRB 
in the UKN1 test system. ASNS was found down-regulated 
by the HDACis. In this context, it has been reported that 
recessive loss-of-function mutations of ASNS in patients 
caused congenital microcephaly, intellectual disability and 
progressive cerebral atrophy. It has also been demonstrated 
that asparagine depletion due to ASNS deficiency results in 
neurological impairment in knockout mice (Ruzzo et al. 
2013). Mutations in the COL11A1 gene have been found 
in patients with Marshall syndrome and Stickler syndrome, 
which share similar phenotypes, such as craniofacial abnor-
malities, a flat nasal bridge, midface hypoplasia, a short 
nose, palate defects and hearing loss (Annunen et al. 1999). 
Mutations in GBE1 have been detected in patients of adult 
polyglucosan body disease with symptoms such as pro-
gressive gait difficulty, urinary incontinence, and reduced 
reflexes in lower limbs (Sampaolo et al. 2015). In the pre-
sent study, COL11A1 and GBE1 were found to be down-
regulated by the incubation of the hESCs with the HDA-
Cis. Mutations in EDNRB have been identified in patients 
suffering from Hirschsprung’s disease, which is character-
ized by the absence of neural crest-derived intramural gan-
glia along the colon (McCallion and Chakravarti 2001). 
MIAT was found to be down-regulated in the present study. 
Although this gene is not translated to protein, it transcribes 
non-coding functional RNA. Recently, SNPs of MIAT have 
been identified in human patients with myocardial infarc-
tion and schizophrenia (Ishii et al. 2006; Rao et al. 2015).
PRSS23, which was found to be down-regulated in our 
study, encodes for a novel serine protease that is expressed 
during the development of the cardiovascular system, and 
it is involved in valvulogenesis of zebrafish. PRSS23 plays 
a significant role in the endothelial to mesenchymal transi-
tion during valvulogenesis, and the knockdown of the gene 
results in atrioventricular defects (Chen et al. 2013). FOXD3 
was found to be up-regulated, and it is linked with congenital 
eye deformities such as aniridia, Peter’s anomaly and ano-
phthalmia in humans (Kloss et al. 2012). RTN1 plays a role 
in the vesicular transport of Spastin, which is involved in 
microtubule dynamics. The disruption of Spastin-mediated 
vesicular transport has been discussed as a cause of heredi-
tary spastic paraplegias, with symptoms such as the pro-
gressive stiffness of lower limbs due to nerve dysfunction, 
cognitive impairments and deafness (Mannan et al. 2006). 
Other diagnostic consensus genes with disease relevance are 
GABRB2, ARNT2, DNER and CASP8. The overexpression 
of DNER inhibits the proliferation of neural progenitor cells 
and induces glial cell differentiation in zebrafish (Hsieh et al. 
2013). A loss-of-function mutation of DNER in mice impairs 
cerebellar functions (Tohgo et al. 2006). ARNT2 was found 
to be down-regulated in the present study. A loss-of-function 
mutation of ARNT2 in humans results in Webb–Dattani syn-
drome, with characteristic features such as microcephaly, 
visual impairment and urinary abnormalities (Webb et al. 
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2013). Caspase 8 was up-regulated by the HDACis and has 
been described to regulate neuronal apoptosis involved in 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s 
and Huntington’s disease in humans (Ahmad et al. 2014). In 
conclusion, the involvement of the diagnostic genes dereg-
ulated by mercurials and HDACis by both test systems in 
developmental toxicity in humans and experimental animals 
has been well established.
A limitation of the present study is the relatively small 
number of test compounds. A next important step will be 
to include compounds with very low cytotoxicity (‘nega-
tive controls’) as well as cytotoxic compounds that are 
known to cause adverse effects other than developmental 
toxicity. The extrapolation from a hazardous test condition 
in vitro, e.g. defined by a high Dp or Di, to adverse devel-
opmental effects in vivo remains difficult. One challenge 
is to simulate the concentrations of a test compound at the 
target cell of toxicity in vivo. Although physiologically 
based pharmacokinetic (PBPK) modelling addresses this 
aspect, its predictions are still associated with a relatively 
high degree of uncertainty. A further limitation that has to 
be taken into account is that in vitro systems do not neces-
sarily recapitulate all in vivo relevant mechanisms. Despite 
these limitations, the concept proposed here with develop-
mental potency and ratio indices quantitatively provides 
information regarding the propensity of test compounds to 
interfere with the complex transcriptional process required 
for normal human development. In conclusion, this study 
offers a concept for the identification of potential develop-
mental toxicity hazards by establishing Dp and Di, which 
predict the propensity of test compounds to interfere with 
transcriptional processes during human development.
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